Is there any role for "adjuvant" therapy for completely resected oligometastatic RCC?

The data re: adjuvant therapy for either high risk (bulky or node positive primary renal cell cancer) or completely resected metastatic renal cell cancer (either synchronous or metachronous) remains largely negative. Trials conducted with cytokines or with a variety of multi kinase inhibitors (sunit...

The role for adjuvant therapy has evolved over the last 5 years with the release of the KEYNOTE-564 study of adjuvant pembrolizumab vs placebo for intermediate- and high-risk M0 and resected M1 clear-cell renal cell cancer, and now most recently with the publication of the LITESPARK-022 trial of adj...